ContraVir Pharmaceuticals, Inc. - Focused on the Development and Commercialization of Targeted Antiviral Therapies

SNNLive spoke with James Sapirstein, CEO of ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) at The MicroCap Conference 2017 in New York City, NY.

Share With

Wednesday, February 07, 2018

ContraVir (NASDAQ: CTRV) is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV), according to the company’s website (see here: www.contravir.com).

SNNLive spoke with James Sapirstein, CEO of ContraVir Pharmaceuticals, Inc. at The MicroCap Conference 2017 in New York City, NY, and they discuss the following topics:

- Overview and history of ContraVir Pharmaceuticals, Inc.

- How what they are developing is different from what is currently available

- Clinical development

- Size of target patient market

- Growth drivers

- Causes of Hepatitis B

For more information about ContraVir Pharmaceuticals, Inc., please visit: www.contravir.com

The interview may contain forward-looking statements about ContraVir Pharmaceuticals, Inc. See ContraVir Pharmaceuticals, Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.